The results of transactivation experiments showed that darolutamide and its two optical isomers and major metabolite-keto-darolutamide showed strong competitive antagonism against AR wild type, which have differences in inhibiting AR activity in prostate cancer VCaP, LAPC-4, and LN CaP cell lines. This evidence concerns the gene AR and Familial prostate cancer.